Bullish for COHANCE/SUVENPHAR: CRAMS Arm Drives High Margins

The article analyzes Cohance Life Science (formerly Suven Pharma), focusing on its demerged Contract Research And Manufacturing Services (CRAMS) arm. It highlights that CRAMS accounted for 95% of the company's top line in 2013-14, growing at a 20% CAGR to ₹514 crore turnover, and is a very high-margin business.

This detailed business analysis is crucial for investors as it sheds light on the core profitability driver of Cohance Life Science. The high-margin nature of the CRAMS business suggests strong earnings potential and operational efficiency, which are key factors for stock valuation in the Indian pharma sector.

This analysis is positive for COHANCE (Cohance Life Science) and SUVENPHAR (Suven Pharmaceuticals Ltd), as it underscores the robust fundamentals of their key business segment. Investors may view this as a strong indicator for future growth and profitability, potentially leading to increased investor interest.

Traders should monitor Cohance Life Science's future financial reports for continued growth in its CRAMS segment and any updates on its New Chemical Entity (NCE) pipeline. Further analysis on the NCE segment's cash burn and potential returns will also be important.

• •Cohance life science (older name Suven Pharma) is the demerged CRAMS Arm of Suven Life Sciences.
• •CRAMS segment accounted for 95% of the Company's top line in 2013-14.
• •CRAMS business grew 20% CAGR over 10 years leading to INR 514 crore turnover.
• •CRAMS is a very high margin business, reason for company to have high ROCE, ROE.
• •New Chemical Entity (NCE) is a cash guzzling unit, with 338 crore spent on drug discovery.